title: p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
abstract: BACKGROUND
  Women with ductal hyperplasia including usual ductal hyperplasia (UDH) and atypical ductal hyperplasia (ADH) have an increased risk of developing invasive ductal carcinoma (IDC) of breast. The importance of several molecular markers in breast cancer has been of considerable interest during recent years such as p53 and estrogen receptor alpha (ERalpha). However, p53 nuclear accumulation and ERalpha expression have not been assessed in ductal hyperplasia co-existing with ductal carcinoma in situ (DCIS) or IDC versus pure ductal hyperplasia without DCIS or IDC.
  
  
  METHODS
  We investigated p53 nuclear accumulation and ERalpha expression in breast ductal hyperplasia in a cohort of 215 Chinese women by immunohistochemistry (IHC), which included 129 cases of pure ductal hyperplasia, 86 cases of ductal hyperplasia co-existing with DCIS (41 cases) or IDC (45 cases).
  
  
  RESULTS
  Nuclear p53 accumulation was identified in 22.8% of ADH (31/136), 41.5% of DCIS (17/41) and 42.2% of IDC (19/45), and no case of UDH (0/79). No difference in nuclear p53 accumulation was observed between pure ADH and ADH co-existing with DCIS (ADH/DCIS) or IDC (ADH/IDC) (P>0.05). The positive rate of ERalpha expression was lower in ADH (118/136, 86.8%) than that in UDH (79/79, 100%) (P<0.001), but higher than that in DCIS (28/41, 68.3%) or IDC (26/45, 57.8%) respectively (P<0.001). The frequency of ERalpha expression was lower in ADH/DCIS (23/29, 79.31%) and ADH/IDC (23/30, 76.67%) than that in pure ADH (72/77, 93.51%) respectively (P<0.05). There was a negative weak correlation between p53 nuclear accumulation and ERalpha expression as for ADH (coefficient correlation -0.51; P<0.001).
  
  
  CONCLUSIONS
  Different pathological types of ductal hyperplasia of breast are accompanied by diversity in patterns of nuclear p53 accumulation and ERalpha expression. At least some pure ADH is molecularly distinct from ADH/CIS or ADH/IDC which indicated the two types of ADH are molecularly distinct entities although they have the same morphological appearance.
authors: Department of Breast Surgery, Research Unit of General Surgery, the First Affiliated Hospital of China Medical University, and Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences of China Medical University, Shenyang, Liaoning Province, (110001), China.
authors: Xiao-yun
authors: XY
authors: Mao
authors: Chui-feng
authors: CF
authors: Fan
authors: Hua-chuan
authors: HC
authors: Zheng
authors: Jing
authors: J
authors: Wei
authors: Fan
authors: F
authors: Yao
authors: Feng
authors: F
authors: Jin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry* / Q000473:pathology; D002467:Cell Nucleus / Q000737:chemistry*; D016009:Chi-Square Distribution; D002681:China; D015331:Cohort Studies; D018450:Disease Progression; D047628:Estrogen Receptor alpha / Q000032:analysis*; D005260:Female; D006801:Humans; D006965:Hyperplasia; D007150:Immunohistochemistry; D008875:Middle Aged; D011230:Precancerous Conditions / Q000737:chemistry* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D055815:Young Adult
chemical_list: D047628:Estrogen Receptor alpha; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53